Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Inflammation and Vascular Ageing: From Telomeres to Novel Emerging Mechanisms.

Chiriacò M, Georgiopoulos G, Duranti E, Antonioli L, Puxeddu I, Nannipieri M, Rosada J, Blandizzi C, Taddei S, Virdis A, Masi S.

High Blood Press Cardiovasc Prev. 2019 Jul 19. doi: 10.1007/s40292-019-00331-7. [Epub ahead of print]

PMID:
31325087
2.

High Levels of β-Amyloid, Tau, and Phospho-Tau in Red Blood Cells as Biomarkers of Neuropathology in Senescence-Accelerated Mouse.

Piccarducci R, Pietrobono D, Pellegrini C, Daniele S, Fornai M, Antonioli L, Trincavelli ML, Blandizzi C, Martini C.

Oxid Med Cell Longev. 2019 Jun 9;2019:5030475. doi: 10.1155/2019/5030475. eCollection 2019.

3.

The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Antonioli L, Blandizzi C, Pacher P, Haskó G.

Pharmacol Rev. 2019 Jul;71(3):345-382. doi: 10.1124/pr.117.014878. Review.

4.

Phytochemicals as Novel Therapeutic Strategies for NLRP3 Inflammasome-Related Neurological, Metabolic, and Inflammatory Diseases.

Pellegrini C, Fornai M, Antonioli L, Blandizzi C, Calderone V.

Int J Mol Sci. 2019 Jun 13;20(12). pii: E2876. doi: 10.3390/ijms20122876. Review.

5.

Microvascular Endothelial Dysfunction in Patients with Obesity.

Virdis A, Masi S, Colucci R, Chiriacò M, Uliana M, Puxeddu I, Bernardini N, Blandizzi C, Taddei S.

Curr Hypertens Rep. 2019 Apr 4;21(4):32. doi: 10.1007/s11906-019-0930-2. Review.

PMID:
30949772
6.

Is There a Risk of Lymphoma Associated With Anti-tumor Necrosis Factor Drugs in Patients With Inflammatory Bowel Disease? A Systematic Review of Observational Studies.

Ferraro S, Leonardi L, Convertino I, Blandizzi C, Tuccori M.

Front Pharmacol. 2019 Mar 19;10:247. doi: 10.3389/fphar.2019.00247. eCollection 2019.

7.

P2X4 receptors, immunity, and sepsis.

Antonioli L, Blandizzi C, Fornai M, Pacher P, Lee HT, Haskó G.

Curr Opin Pharmacol. 2019 Mar 25;47:65-74. doi: 10.1016/j.coph.2019.02.011. [Epub ahead of print] Review.

PMID:
30921560
8.

Constipation, deficit in colon contractions and alpha-synuclein inclusions within the colon precede motor abnormalities and neurodegeneration in the central nervous system in a mouse model of alpha-synucleinopathy.

Rota L, Pellegrini C, Benvenuti L, Antonioli L, Fornai M, Blandizzi C, Cattaneo A, Colla E.

Transl Neurodegener. 2019 Feb 6;8:5. doi: 10.1186/s40035-019-0146-z. eCollection 2019.

9.

Rethinking Communication in the Immune System: The Quorum Sensing Concept.

Antonioli L, Blandizzi C, Pacher P, Guilliams M, Haskó G.

Trends Immunol. 2019 Feb;40(2):88-97. doi: 10.1016/j.it.2018.12.002. Epub 2019 Jan 2. Review.

PMID:
30611647
10.

Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for Mycobacterium avium subspecies paratuberculosis in Crohn's disease: pharmacological and clinical implications.

Savarino E, Bertani L, Ceccarelli L, Bodini G, Zingone F, Buda A, Facchin S, Lorenzon G, Marchi S, Marabotto E, De Bortoli N, Savarino V, Costa F, Blandizzi C.

Expert Opin Biol Ther. 2019 Feb;19(2):79-88. doi: 10.1080/14712598.2019.1561852. Epub 2019 Jan 2. Review.

PMID:
30574820
11.

A Comparative Study on the Efficacy of NLRP3 Inflammasome Signaling Inhibitors in a Pre-clinical Model of Bowel Inflammation.

Pellegrini C, Fornai M, Colucci R, Benvenuti L, D’Antongiovanni V, Natale G, Fulceri F, Giorgis M, Marini E, Gastaldi S, Bertinaria M, Blandizzi C, Antonioli L.

Front Pharmacol. 2018 Dec 3;9:1405. doi: 10.3389/fphar.2018.01405. eCollection 2018.

12.

Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention.

Colucci R, Pellegrini C, Fornai M, Tirotta E, Antonioli L, Renzulli C, Ghelardi E, Piccoli E, Gentile D, Benvenuti L, Natale G, Fulceri F, Palazón-Riquelme P, López-Castejón G, Blandizzi C, Scarpignato C.

Front Pharmacol. 2018 Nov 29;9:1340. doi: 10.3389/fphar.2018.01340. eCollection 2018.

13.

Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables.

Niccoli L, Nannini C, Blandizzi C, Mantarro S, Mosca M, Di Munno O, Goletti D, Benucci M, Gobbi FL, Cassarà E, Kaloudi O, Cantini F.

Ther Clin Risk Manag. 2018 Oct 24;14:2097-2111. doi: 10.2147/TCRM.S175772. eCollection 2018.

14.

Risankizumab for the treatment of moderate to severe psoriasis.

Chiricozzi A, Antonioli L, Panduri S, Fornai M, Romanelli M, Blandizzi C.

Expert Opin Biol Ther. 2019 Jan;19(1):1-8. doi: 10.1080/14712598.2019.1551354. Epub 2018 Nov 27.

PMID:
30462554
15.

Aging Modulates the Influence of Arginase on Endothelial Dysfunction in Obesity.

Masi S, Colucci R, Duranti E, Nannipieri M, Anselmino M, Ippolito C, Tirotta E, Georgiopoulos G, Garelli F, Nericcio A, Segnani C, Bernardini N, Blandizzi C, Taddei S, Virdis A.

Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2474-2483. doi: 10.1161/ATVBAHA.118.311074.

PMID:
30354211
16.

Luteolin Prevents Cardiometabolic Alterations and Vascular Dysfunction in Mice With HFD-Induced Obesity.

Gentile D, Fornai M, Pellegrini C, Colucci R, Benvenuti L, Duranti E, Masi S, Carpi S, Nieri P, Nericcio A, Garelli F, Virdis A, Pistelli L, Blandizzi C, Antonioli L.

Front Pharmacol. 2018 Sep 25;9:1094. doi: 10.3389/fphar.2018.01094. eCollection 2018.

17.

The usefulness of listening social media for pharmacovigilance purposes: a systematic review.

Convertino I, Ferraro S, Blandizzi C, Tuccori M.

Expert Opin Drug Saf. 2018 Nov;17(11):1081-1093. doi: 10.1080/14740338.2018.1531847. Epub 2018 Oct 12. Review.

PMID:
30285501
18.

Potential Direct Costs of Adverse Drug Events and Possible Cost Savings Achievable by their Prevention in Tuscany, Italy: A Model-Based Analysis.

Convertino I, Salvadori S, Pecori A, Galiulo MT, Ferraro S, Parrilli M, Corona T, Turchetti G, Blandizzi C, Tuccori M.

Drug Saf. 2019 Mar;42(3):427-444. doi: 10.1007/s40264-018-0737-0.

PMID:
30276630
19.

Microvascular Endothelial Dysfunction in Human Obesity: Role of TNF-α.

Virdis A, Colucci R, Bernardini N, Blandizzi C, Taddei S, Masi S.

J Clin Endocrinol Metab. 2019 Feb 1;104(2):341-348. doi: 10.1210/jc.2018-00512.

PMID:
30165404
20.

Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity.

Antonioli L, Caputi V, Fornai M, Pellegrini C, Gentile D, Giron MC, Orso G, Bernardini N, Segnani C, Ippolito C, Csóka B, Haskó G, Németh ZH, Scarpignato C, Blandizzi C, Colucci R.

Int J Obes (Lond). 2019 Feb;43(2):331-343. doi: 10.1038/s41366-018-0166-2. Epub 2018 Aug 6.

PMID:
30082748
21.

Neuronal regulation of intestinal immune functions in health and disease.

Fornai M, van den Wijngaard RM, Antonioli L, Pellegrini C, Blandizzi C, de Jonge WJ.

Neurogastroenterol Motil. 2018 Dec;30(12):e13406. doi: 10.1111/nmo.13406. Epub 2018 Jul 29. Review.

PMID:
30058092
22.

Quorum sensing in the immune system.

Antonioli L, Blandizzi C, Pacher P, Guilliams M, Haskó G.

Nat Rev Immunol. 2018 Sep;18(9):537-538. doi: 10.1038/s41577-018-0040-4. No abstract available.

PMID:
30006523
23.

The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment.

Stasi C, Caserta A, Nisita C, Cortopassi S, Fani B, Salvadori S, Pancetti A, Bertani L, Gambaccini D, de Bortoli N, Dell'Osso L, Blandizzi C, Marchi S, Bellini M.

J Gastroenterol Hepatol. 2019 Apr;34(4):713-719. doi: 10.1111/jgh.14375. Epub 2018 Jul 27.

PMID:
29971822
24.

Letter: can the overall gastrointestinal safety of celecoxib be extended to all COX-2-selective agents?

Scarpignato C, Blandizzi C.

Aliment Pharmacol Ther. 2018 Jul;48(1):108-110. doi: 10.1111/apt.14810. No abstract available.

PMID:
29882981
25.

Dietary flavonoids as a potential intervention to improve redox balance in obesity and related co-morbidities: a review.

Gentile D, Fornai M, Pellegrini C, Colucci R, Blandizzi C, Antonioli L.

Nutr Res Rev. 2018 Dec;31(2):239-247. doi: 10.1017/S0954422418000082. Epub 2018 Jun 6. Review.

PMID:
29871706
26.

Interplay among gut microbiota, intestinal mucosal barrier and enteric neuro-immune system: a common path to neurodegenerative diseases?

Pellegrini C, Antonioli L, Colucci R, Blandizzi C, Fornai M.

Acta Neuropathol. 2018 Sep;136(3):345-361. doi: 10.1007/s00401-018-1856-5. Epub 2018 May 24. Review.

PMID:
29797112
27.

Adenosine signaling and the immune system: When a lot could be too much.

Antonioli L, Fornai M, Blandizzi C, Pacher P, Haskó G.

Immunol Lett. 2019 Jan;205:9-15. doi: 10.1016/j.imlet.2018.04.006. Epub 2018 Apr 24. Review.

PMID:
29702147
28.

The flavonoid compound apigenin prevents colonic inflammation and motor dysfunctions associated with high fat diet-induced obesity.

Gentile D, Fornai M, Colucci R, Pellegrini C, Tirotta E, Benvenuti L, Segnani C, Ippolito C, Duranti E, Virdis A, Carpi S, Nieri P, Németh ZH, Pistelli L, Bernardini N, Blandizzi C, Antonioli L.

PLoS One. 2018 Apr 11;13(4):e0195502. doi: 10.1371/journal.pone.0195502. eCollection 2018.

29.

Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases.

Dal Ben D, Antonioli L, Lambertucci C, Fornai M, Blandizzi C, Volpini R.

Front Pharmacol. 2018 Mar 14;9:212. doi: 10.3389/fphar.2018.00212. eCollection 2018. Review.

30.

Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis.

Antonioli L, El-Tayeb A, Pellegrini C, Fornai M, Awwad O, Giustarini G, Natale G, Ryskalin L, Németh ZH, Müller CE, Blandizzi C, Colucci R.

Purinergic Signal. 2018 Mar;14(1):27-36. doi: 10.1007/s11302-017-9591-2. Epub 2017 Nov 8.

31.

Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges.

Blandizzi C, Galeazzi M, Valesini G.

Pharmacol Res. 2018 Feb;128:306-314. doi: 10.1016/j.phrs.2017.10.015. Epub 2017 Nov 3. Review.

32.

Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors.

Antonioli L, Pellegrini C, Fornai M, Tirotta E, Gentile D, Benvenuti L, Giron MC, Caputi V, Marsilio I, Orso G, Bernardini N, Segnani C, Ippolito C, Csóka B, Németh ZH, Haskó G, Scarpignato C, Blandizzi C, Colucci R.

Purinergic Signal. 2017 Dec;13(4):497-510. doi: 10.1007/s11302-017-9577-0. Epub 2017 Aug 14.

33.

Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.

Tuccori M, Convertino I, Galiulo MT, Marino A, Capogrosso-Sansone A, Blandizzi C.

Expert Opin Drug Saf. 2017 Oct;16(10):1133-1148. doi: 10.1080/14740338.2017.1361401. Epub 2017 Aug 4. Review.

PMID:
28748718
34.

Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.

Capogrosso Sansone A, Convertino I, Galiulo MT, Salvadori S, Pieroni S, Knezevic T, Mantarro S, Marino A, Hauben M, Blandizzi C, Tuccori M.

Drug Saf. 2017 Oct;40(10):895-909. doi: 10.1007/s40264-017-0564-8.

PMID:
28681266
35.

Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies.

Antonioli L, Novitskiy SV, Sachsenmeier KF, Fornai M, Blandizzi C, Haskó G.

Drug Discov Today. 2017 Nov;22(11):1686-1696. doi: 10.1016/j.drudis.2017.06.005. Epub 2017 Jul 1. Review.

PMID:
28676406
36.

Vonoprazan fumarate for the management of acid-related diseases.

Martinucci I, Blandizzi C, Bodini G, Marabotto E, Savarino V, Marchi S, de Bortoli N, Savarino E.

Expert Opin Pharmacother. 2017 Aug;18(11):1145-1152. doi: 10.1080/14656566.2017.1346087. Epub 2017 Jul 6. Review.

PMID:
28657473
37.

Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.

Sferrazza G, Siviero PD, Nicotera G, Turella P, Serafino A, Blandizzi C, Pierimarchi P.

Expert Rev Clin Pharmacol. 2017 Sep;10(9):1007-1019. doi: 10.1080/17512433.2017.1348227. Epub 2017 Jul 6. Review.

PMID:
28656793
38.

Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration.

Pellegrini C, Antonioli L, Colucci R, Tirotta E, Gentile D, Ippolito C, Segnani C, Levandis G, Cerri S, Blandini F, Barocelli E, Ballabeni V, Bernardini N, Blandizzi C, Fornai M.

Neuropharmacology. 2017 Sep 1;123:22-33. doi: 10.1016/j.neuropharm.2017.05.016. Epub 2017 May 17.

PMID:
28526609
39.

Clinical differences among the elderly admitted to the emergency department for accidental or unexplained falls and syncope.

Pasqualetti G, Calsolaro V, Bini G, Dell'Agnello U, Tuccori M, Marino A, Capogrosso-Sansone A, Rafanelli M, Santini M, Orsitto E, Ungar A, Blandizzi C, Monzani F.

Clin Interv Aging. 2017 Apr 13;12:687-695. doi: 10.2147/CIA.S127824. eCollection 2017.

40.

Comparing Originator Biologics and Biosimilars: A Review of the Relevant Issues.

Blandizzi C, Meroni PL, Lapadula G.

Clin Ther. 2017 May;39(5):1026-1039. doi: 10.1016/j.clinthera.2017.03.014. Epub 2017 Apr 15. Review.

PMID:
28416374
41.

Development of an Acrylate Derivative Targeting the NLRP3 Inflammasome for the Treatment of Inflammatory Bowel Disease.

Cocco M, Pellegrini C, Martínez-Banaclocha H, Giorgis M, Marini E, Costale A, Miglio G, Fornai M, Antonioli L, López-Castejón G, Tapia-Abellán A, Angosto D, Hafner-Bratkovič I, Regazzoni L, Blandizzi C, Pelegrín P, Bertinaria M.

J Med Chem. 2017 May 11;60(9):3656-3671. doi: 10.1021/acs.jmedchem.6b01624. Epub 2017 Apr 24.

PMID:
28410442
42.

Extra-esophageal presentation of gastroesophageal reflux disease: new understanding in a new era.

Martinucci I, Albano E, Marchi S, Blandizzi C.

Minerva Gastroenterol Dietol. 2017 Sep;63(3):221-234. doi: 10.23736/S1121-421X.17.02393-5. Epub 2017 Mar 3. Review.

PMID:
28260352
43.

Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation.

Pellegrini C, Antonioli L, Lopez-Castejon G, Blandizzi C, Fornai M.

Front Immunol. 2017 Jan 25;8:36. doi: 10.3389/fimmu.2017.00036. eCollection 2017. Review.

44.

Expected and actual adverse drug-drug interactions in elderly patients accessing the emergency department: data from the ANCESTRAL-ED study.

Marino A, Capogrosso-Sansone A, Tuccori M, Bini G, Calsolaro V, Mantarro S, Convertino I, Pasqualetti G, Orsitto E, Santini M, Monzani F, Blandizzi C; ANCESTRAL-ED Study Group.

Expert Opin Drug Saf. 2016 Dec;15(sup2):45-50.

PMID:
27875918
45.

Hepatitis C virus infection: opportunities for an earlier detection in primary care.

Lapi F, Capogrosso Sansone A, Mantarro S, Simonetti M, Tuccori M, Blandizzi C, Rossi A, Corti G, Bartoloni A, Bellia A, Baiocchi L, Cricelli I, Cricelli C.

Eur J Gastroenterol Hepatol. 2017 Mar;29(3):271-276. doi: 10.1097/MEG.0000000000000785.

PMID:
27849644
46.

Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners.

BMC Med. 2016 Nov 9;14(1):179. Review.

47.

Anti-CD73 immunotherapy: A viable way to reprogram the tumor microenvironment.

Antonioli L, Blandizzi C, Malavasi F, Ferrari D, Haskó G.

Oncoimmunology. 2016 Jul 29;5(9):e1216292. eCollection 2016.

48.

Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD.

de Bortoli N, Frazzoni L, Savarino EV, Frazzoni M, Martinucci I, Jania A, Tolone S, Scagliarini M, Bellini M, Marabotto E, Furnari M, Bodini G, Russo S, Bertani L, Natali V, Fuccio L, Savarino V, Blandizzi C, Marchi S.

Am J Gastroenterol. 2016 Dec;111(12):1711-1717. doi: 10.1038/ajg.2016.432. Epub 2016 Sep 20.

PMID:
27644732
49.

Intestinal dysfunction in Parkinson's disease: Lessons learned from translational studies and experimental models.

Pellegrini C, Colucci R, Antonioli L, Barocelli E, Ballabeni V, Bernardini N, Blandizzi C, de Jonge WJ, Fornai M.

Neurogastroenterol Motil. 2016 Dec;28(12):1781-1791. doi: 10.1111/nmo.12933. Epub 2016 Sep 9. Review.

PMID:
27611012
50.

Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.

Savarino E, Martinucci I, Furnari M, Romana C, Pellegatta G, Moscatelli A, Bodini G, Marabotto E, Savarino V, de Bortoli N, Blandizzi C.

Expert Opin Drug Metab Toxicol. 2016 Nov;12(11):1333-1341. doi: 10.1080/17425255.2016.1214714. Epub 2016 Aug 8.

PMID:
27428571

Supplemental Content

Loading ...
Support Center